Home

Merck & Co (MRK)

84.18
+0.00 (0.00%)
NYSE · Last Trade: Sep 4th, 7:25 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
3 Things You Need to Know if You Buy Pfizer Todayfool.com
Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?
Via The Motley Fool · September 4, 2025
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirementsbenzinga.com
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
Via Benzinga · September 4, 2025
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster'benzinga.com
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.
Via Benzinga · September 4, 2025
Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Tradesbenzinga.com
Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance.
Via Benzinga · September 3, 2025
Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trialstocktwits.com
Via Stocktwits · September 2, 2025
CSX, Intel, Palantir, Nvidia, Merck: What Sparked Heavy After-Hours Trading In These 5 Stocks?stocktwits.com
Via Stocktwits · August 20, 2025
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?fool.com
Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.
Via The Motley Fool · September 2, 2025
This Merck Pill Promises Powerful Cholesterol Reduction Without Injectionsbenzinga.com
Merck's Coralreef Lipids trial showed enlicitide cut LDL-C and other lipid markers, while pooled Verquvo data hinted at heart failure benefits.
Via Benzinga · September 2, 2025
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 We Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Via StockStory · September 1, 2025
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepensbenzinga.com
Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez.
Via Benzinga · August 30, 2025
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stockchartmill.com
Discover Merck (MRK), a top dividend stock with a 3.76% yield, strong growth history, and excellent financial health for sustainable income.
Via Chartmill · August 30, 2025
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'benzinga.com
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
Via Benzinga · August 29, 2025
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via StockStory · August 28, 2025
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analystbenzinga.com
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger.
Via Benzinga · August 27, 2025
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Via MarketMinute · August 27, 2025
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Bigbenzinga.com
EU set to scrap tariffs on U.S. goods in a key auto trade deal. See which American industrial and energy stocks are poised for a boost.
Via Benzinga · August 27, 2025
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upsidestocktwits.com
Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.
Via Stocktwits · August 26, 2025
As the Market Rotates, This Healthcare ETF Is Leading the Waymarketbeat.com
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.
Via MarketBeat · August 26, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · August 25, 2025
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cutsmarketbeat.com
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut.
Via MarketBeat · August 25, 2025
HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platformbenzinga.com
HCW Biologics shares jump after unveiling TRBC-based fusion therapy that enhances immune response and shows strong preclinical results in solid tumors.
Via Benzinga · August 25, 2025
What's going on in today's session: S&P500 moverschartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via Chartmill · August 21, 2025
Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Millionfool.com
Via The Motley Fool · August 21, 2025
2 Value Stocks on Our Watchlist and 1 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · August 18, 2025
2 Top Dividend Stocks to Buy on the Dipfool.com
These blue chip healthcare stocks could still deliver strong long-term returns.
Via The Motley Fool · August 16, 2025